Amgen to Acquire Rodeo Therapeutics for ~$721M
Shots:
- Amgen to acquire all outstanding shares of Rodeo for a $55M upfront along with ~$666M in cash as contingent milestones
- The acquisition will strengthen Amgen's inflammation portfolio with the addition of Rodeo's 15-PGDH program
- Rodeo’s 15-PGDH has the potential in its preclinical studies and have clinical potential in multiple indications
Ref: PRNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
